Gene Therapy Pioneer James Wilson Joins RSRT Consortium; Resigns from Advisory Role at IPO-Bound Solid Biosciences

James M. Wilson, M.D., Ph.D., has joined the Gene Therapy Consortium of the Rett Syndrome Research Trust (RSRT), the Trust said today—10 days after the disclosure that he resigned from the Scientific Advisory Board of Solid Biosciences, which is set to begin an initial public offering (IPO) today.RSRT said it will fund the research of Dr. Wilson, director of the University of Pennsylvania Gene Therapy Program and the Rose H. Weiss Orphan Disease Center. His lab will receive an award of $1.